A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.

ConditionLichen Simplex Chronicus

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-45

SponsorPrime Gene Therapeutics Co., Ltd.

About this trial

The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.

Eligibility criteria

Qualifiers

1. Read, understood, and signed an ICF before any investigational procedure(s) are performed..

Disqualifiers

1. Participants with clinically significant abnormal electrocardiogram results judged by the investigator during screening.

Trial design

Treatments tested in this trial

PG-033 tablets
PG-033 placebo comparator

Treatment groups

30 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Prime Gene Therapeutics Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov